VIRTUAL CONSULT

Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

A special audio supplement to a CME symposium held during the 2016 American Society of Clinical Oncology Annual Meeting featuring expert comments on the application of emerging research to patient care

Faculty Interviews

Robert Z Orlowski, MD, PhD

Brad S Kahl, MD

Editor

Neil Love, MD

Contents

1 Audio CD

ABIM CME MOC ACCREDITED

From the publishers of: Hematologic Oncology™ UPDATE

CME Certified

Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/VirtualConsult16

Follow us at Facebook.com/ResearchToPractice Follow us on Twitter @DrNeilLove

Hematologic Oncology™ UPDATE

Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131
	Fax: (305) 377-9998
	Email: DrNeilLove@ResearchToPractice.com
For CME/CNE Information	Email: CE@ResearchToPractice.com

Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia — A Continuing Medical Education Activity

OVERVIEW OF ACTIVITY

Taken together, it is estimated that approximately 111,410 new lymphoma and myeloma cases will be identified in the United States in the year 2016, and 33,920 individuals will die from these diseases. Importantly, more than 65 drug products are currently labeled for use in the treatment of common hematologic cancers, comprising at least 122 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

This special audio supplement to a CME satellite symposium held during the 2016 ASCO Annual Meeting uses one-to-one interviews with one leading investigator in lymphoma and one in multiple myeloma (MM) who served as faculty to discuss cases and questions submitted by attendees. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the transplant and nontransplant settings, considering patient- and disease-related factors.
- Appraise recent data on therapeutic advances and changing practice standards in the management of MM, and integrate this information, as appropriate, into current clinical care.
- Appreciate the FDA approvals of novel targeted agents — ibrutinib, idelalisib, obinutuzumab and venetoclax — for the treatment of chronic lymphocytic leukemia, and discern how these therapies can be appropriately integrated into the clinical management of standard- and high-risk disease.
- Recognize the role of novel agents in the management of indolent and aggressive lymphomas, and ensure appropriate supportive care measures to minimize side effects.
- Incorporate new therapeutic strategies into the best-practice management of Hodgkin lymphoma.
- Assess the ongoing clinical trials investigating innovative approaches for Hodgkin and non-Hodgkin lymphomas and MM, and refer appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**. Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide *aggregate* and *deidentified* data to third parties, including commercial supporters. **We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.**

HOW TO USE THIS CME ACTIVITY

This CME activity consists of an audio component. To receive credit, the participant should listen to the CD and complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at **ResearchToPractice.com/VirtualConsult16/CME**.

This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Seattle Genetics and Takeda Oncology.

Release date: September 2016; Expiration date: September 2017

CME INFORMATION

FACULTY AFFILIATIONS

Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Chair ad Interim, Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
St Louis, Missouri

EDITOR

Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Orlowski** — Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology. **Dr Kahl** — Advisory Committee: Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Interview with Robert Z Orlowski, MD, PhD

Tracks 1-12

Track 1 SWOG-S0777: Results of a Phase III trial of lenalidomide/dexamethasone with or without bortezomib for patients with previously untreated multiple myeloma (MM) without an intent for immediate autologous stem cell transplant (ASCT)

Track 2 Results of the Phase III IFM 2009 trial: ASCT for MM in the era of new drugs

Track 3 Carfilzomib-associated dyspnea

Track 4 Activity and side-effect profiles of the oral proteasome inhibitors ixazomib and oprozomib in MM

Track 5 **Second opinion:** Role of maintenance therapy after delayed ASCT

Track 6 Emerging role of proteasome inhibitors as part of post-transplant maintenance therapy and potential role of ixazomib

Track 7 Perspective on the results of the Phase III CASTOR study of bortezomib/dexamethasone with or without daratumumab for relapsed/refractory (R/R) MM

Track 8 Dose reduction to ameliorate ixazomib-associated gastrointestinal toxicity

Track 9 Clinical experience with daratumumab infusion time and reactions

Track 10 Understanding daratumumab interference with blood compatibility testing

Track 11 POLLUX: Results of a Phase III trial of lenalidomide/dexamethasone with or without daratumumab for R/R MM

Track 12 **Second opinion:** Therapeutic options for patients experiencing disease relapse on lenalidomide maintenance therapy

Interview with Brad S Kahl, MD

Tracks 13-27

Track 13 Optimal integration of ibrutinib and obinutuzumab into the treatment algorithm for chronic lymphocytic leukemia (CLL)

Track 14 Choosing between FCR (fludarabine/cyclophosphamide/rituximab), bendamustine/rituximab and ibrutinib for younger patients with newly diagnosed CLL

Track 15 Activity, tolerability and management of tumor lysis syndrome with the recently FDA-approved Bcl-2 inhibitor venetoclax for patients with del(17p) CLL who have received at least 1 prior therapy

Track 16 Preemptive measures to reduce the risk of tumor lysis syndrome in patients with CLL receiving venetoclax

Track 17 Mechanism of action, tolerability and ongoing investigations of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (ACP-196) in R/R CLL

Track 18 Front-line therapy options for follicular lymphoma (FL) with high tumor burden

Track 19 Obinutuzumab for FL: Activity, management of infusion-related reactions and ongoing investigations

Track 20 Approach to second-line therapy for patients with FL and disease progression on bendamustine/rituximab

Track 21 Efficacy and emerging side effects of the novel PI3K inhibitor copanlisib for patients with indolent non-Hodgkin lymphoma

Track 22 Management of mantle-cell lymphoma in patients experiencing disease progression on ibrutinib

Track 23 Identification and treatment of primary bone diffuse large B-cell lymphoma (DLBCL)

Track 24 Appropriate use of lenalidomide for R/R DLBCL

Track 25 Perspective on the use of brentuximab vedotin as consolidation therapy for patients with Hodgkin lymphoma (HL) at high risk of disease progression after ASCT

Track 26 Activity of anti-PD-1 antibodies in R/R HL

Track 27 Investigating the combination of brentuximab vedotin and immune checkpoint inhibitors for advanced HL

SELECT PUBLICATIONS

CLL

Burger JA et al; RESONATE-2 Investigators. **Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.** *N Engl J Med* 2015;373(25):2425-37.

Byrd JC et al. **Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2016;374(4):323-32.

Byrd JC et al. **Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.** *Blood* 2016;127(1):79-86.

Chanan-Khan A et al. **Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study.** *Lancet Oncol* 2016;17(2):200-11.

Fischer K et al. **Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.** *J Clin Oncol* 2012;30(26):3209-16.

Goede V et al. **Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.** *N Engl J Med* 2014;370(12):1101-10.

Lampson BL et al. **Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities.** *Proc ASH* 2015;**Abstract 497**.

O'Brien SM et al. **A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.** *Blood* 2015;126(25):2686-94.

Roberts AW et al. **Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2016;374(4):311-22.

HL

Ansell SM et al. **PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.** *N Engl J Med* 2015;372(4):311-9.

Moskowitz CH et al. **Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2015;385(9980):1853-62.

Park SI et al. **A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.** *Proc ASCO* 2016;**Abstract 7508**.

Younes A et al. **CheckMate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) — A phase 2 study.** *Proc ASCO* 2016;**Abstract 7535**.

Indolent B-Cell Non-Hodgkin Lymphoma

Dreyling M et al. **Phase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphoma.** *Proc ASH* 2014;**Abstract 1701**.

Evens AM et al. **Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).** *Proc ASCO* 2016;**Abstract 7507**.

Leonard JP et al. **Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance).** *J Clin Oncol* 2015;33(31):3635-40.

Sehn LH et al. **Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study.** *J Clin Oncol* 2015;33(30):3467-74.

Mantle-Cell Lymphoma

Dreyling M et al. **Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study.** *Lancet* 2016;387(10020):770-8.

Rummel M et al. **Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial.** *Lancet Oncol* 2016;17(1):57-66.

Rummel MJ et al. **Two years rituximab maintenance vs observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).** *Proc ASCO* 2016;**Abstract 7503**.

MM

Attal M et al. **Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial).** *Proc ASH* 2015;**Abstract 391**.

Avet-Loiseau H et al. **Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial.** *Proc ASH* 2015;**Abstract 191**.

Dimopoulos MA et al. **An open-label, randomised Phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRD) versus lenalidomide and dexamethasone (RD) in relapsed or refractory multiple myeloma (RRMM): POLLUX.** *Proc EHA* 2016. No abstract available

Durie B et al. **Bortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized Phase III trial SWOG S0777.** *Proc ASH* 2015;**Abstract 25**.

Krishnan AY et al. **A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.** *Proc ASCO* 2016;**Abstract 8008**.

Lacy M et al. **Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).** *Proc ASCO* 2016;**Abstract 8002**.

McBride A et al. **Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma.** *Am J Health Syst Pharm* 2015;72(5):353-60.

Moreau P et al. **Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.** *N Engl J Med* 2016;374(17):1621-34.

Palumbo A et al. **Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.** *Proc ASCO* 2016;**Abstract LBA4**.

Vij R et al. **Clinical profile of single-agent oprozomib in patients (pts) with multiple myeloma (MM): Updated results from a multicenter, open-label, dose escalation Phase 1b/2 study.** *Proc ASH* 2014;**Abstract 34**.

Related Video Program



Visit www.ResearchToPractice.com/VirtualConsult16/Video for the full video proceedings and accompanying slide sets from the related CME event at the 2016 ASCO Annual Meeting. Topics covered include:

Newly diagnosed multiple myeloma (MM) — Robert Z Orlowski, MD, PhD

Relapsed/refractory MM — Sagar Lonial, MD

Chronic lymphocytic leukemia — Brad S Kahl, MD

Hodgkin lymphoma — Ranjana Advani, MD

Follicular and mantle-cell lymphoma — Stephen M Ansell, MD, PhD

Diffuse large B-cell and T-cell lymphoma — Christopher Flowers, MD, MS

POST-TEST

Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

QUESTIONS (PLEASE CIRCLE ANSWER):

1. **Results of the Phase III SWOG-S0777 trial evaluating lenalidomide/dexamethasone with or without bortezomib for patients with previously untreated MM without an intent for immediate ASCT demonstrated significant improvement in _____ with the addition of bortezomib.**
   a. Overall survival
   b. Progression-free survival (PFS)
   c. Both a and b
   d. Neither a nor b

2. **Which of the following oral proteasome inhibitors is FDA approved for the treatment of MM?**
   a. Ixazomib
   b. Oprozomib
   c. Both a and b
   d. Neither a nor b

3. **Results of the Phase III IFM 2009 trial evaluating early ASCT versus additional cycles of lenalidomide/bortezomib/dexamethasone (RVd) after RVd induction therapy for newly diagnosed MM demonstrated a PFS advantage with _____.**
   a. Additional cycles of RVd
   b. Early ASCT
   c. Neither, PFS was equivalent on each arm

4. **In the Phase III POLLUX and CASTOR studies, the addition of daratumumab to which of the following regimens for R/R MM significantly improved PFS?**
   a. Bortezomib/dexamethasone
   b. Lenalidomide/dexamethasone
   c. Both a and b
   d. Neither a nor b

5. **The combination of elotuzumab and lenalidomide/dexamethasone was recently FDA approved for _____.**
   a. Patients with newly diagnosed MM
   b. Patients with MM who have received 1 to 3 prior therapies
   c. Both a and b

6. **Which of the following statements is true of venetoclax in the treatment of CLL?**
   a. It acts by inhibiting Bcl-2
   b. It is not effective in patients with del(17p) CLL
   c. It can cause tumor lysis syndrome
   d. All of the above
   e. Both a and c

7. **What is the mechanism of action of acalabrutinib (ACP-196)?**
   a. Antibody-drug conjugate
   b. BTK inhibitor
   c. Immunomodulatory drug
   d. Proteasome inhibitor

8. **Nivolumab was recently approved by the FDA for patients with classical HL that has relapsed or progressed after _____.**
   a. ASCT
   b. Post-transplant brentuximab vedotin
   c. Both a and b

9. **Which of the following agents is classified as a PI3 kinase inhibitor?**
   a. Copanlisib
   b. Daratumumab
   c. Elotuzumab
   d. Idelalisib
   e. All of the above
   f. Both b and c
   g. Both a and d

10. **Single-agent lenalidomide has demonstrated preferential activity in which of the following phenotypes of DLBCL?**
    a. Germinal center B-cell (GBC) DLBCL
    b. Activated B-cell DLBCL (non-GBC DLBCL)
    c. Neither, lenalidomide activity is equivalent in each phenotype

EDUCATIONAL ASSESSMENT AND CREDIT FORM

Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Implications of the Phase III SWOG-S0777 and IFM 2009 data sets on the selection of induction regimen and the role of transplant for newly diagnosed MM	4 3 2 1	4 3 2 1
Results of Phase III studies of daratumumab in combination with bortezomib/dexamethasone (CASTOR) or with lenalidomide/ dexamethasone (POLLUX) for R/R MM	4 3 2 1	4 3 2 1
Optimal integration of recently approved agents into the treatment algorithm for CLL	4 3 2 1	4 3 2 1
Activity of obinutuzumab in FL, management of infusion-related reactions and ongoing investigations	4 3 2 1	4 3 2 1
Mechanism of action, tolerability and ongoing investigations of the second-generation BTK inhibitor acalabrutinib in R/R CLL	4 3 2 1	4 3 2 1

Practice Setting:

☐ Academic center/medical school ☐ Community cancer center/hospital ☐ Group practice
☐ Solo practice ☐ Government (eg, VA) ☐ Other (please specify).....

Was the activity evidence based, fair, balanced and free from commercial bias?

☐ Yes ☐ No If no, please explain: .....

Please identify how you will change your practice as a result of completing this activity (select all that apply).

☐ This activity validated my current practice
☐ Create/revise protocols, policies and/or procedures
☐ Change the management and/or treatment of my patients
☐ Other (please explain): .....

If you intend to implement any changes in your practice, please provide 1 or more examples:

.....

The content of this activity matched my current (or potential) scope of practice.

☐ Yes ☐ No If no, please explain: .....

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the transplant and nontransplant settings, considering patient- and disease-related factors. . . . . 4 3 2 1 N/M N/A
- Appraise recent data on therapeutic advances and changing practice standards in the management of MM, and integrate this information, as appropriate, into current clinical care. . . . . 4 3 2 1 N/M N/A
- Appreciate the FDA approvals of novel targeted agents — ibrutinib, idelalisib, obinutuzumab and venetoclax — for the treatment of chronic lymphocytic leukemia, and discern how these therapies can be appropriately integrated into the clinical management of standard- and high-risk disease . . . . . 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

As a result of this activity, I will be able to:

- Recognize the role of novel agents in the management of indolent and aggressive lymphomas, and ensure appropriate supportive care measures to minimize side effects. . . . . 4 3 2 1 N/M N/A
- Incorporate new therapeutic strategies into the best-practice management of Hodgkin lymphoma. . . . . 4 3 2 1 N/M N/A
- Assess the ongoing clinical trials investigating innovative approaches for Hodgkin and non-Hodgkin lymphomas and MM, and refer appropriate patients for study participation. . . . . 4 3 2 1 N/M N/A

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

.....

Would you recommend this activity to a colleague?

☐ Yes ☐ No If no, please explain: .....

PART 2 — Please tell us about the faculty and editor for this educational activity

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

Faculty	Knowledge of subject matter	Effectiveness as an educator
Robert Z Orlowski, MD, PhD	4 3 2 1	4 3 2 1
Brad S Kahl, MD	4 3 2 1	4 3 2 1
Editor	**Knowledge of subject matter**	**Effectiveness as an educator**
Neil Love, MD	4 3 2 1	4 3 2 1

REQUEST FOR CREDIT — Please print clearly

Name:..... Specialty:.....

Professional Designation:
☐ MD ☐ DO ☐ PharmD ☐ NP ☐ RN ☐ PA ☐ Other .....

Street Address:..... Box/Suite:.....

City, State, Zip:.....

Telephone:..... Fax:.....

Email:.....

Research To Practice designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature:..... Date:.....

☐ **I would like Research To Practice to submit my CME credits to the ABIM to count toward my MOC points. I understand that because I am requesting MOC credit, Research To Practice will be required to share personally identifiable information with the ACCME and ABIM.**

Additional information for MOC credit (required):

Date of Birth (Month and Day Only): __ __ / __ __ ABIM 6-Digit ID Number:.....

If you are not sure of your ABIM ID, please visit http://www.abim.org/online/findcand.aspx.

The expiration date for this activity is September 2017. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/VirtualConsult16/CME.

QID 1659

Neil Love, MD
Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Seattle Genetics and Takeda Oncology.

Research
To Practice®

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Release date: September 2016
Expiration date: September 2017
Estimated time to complete: 1.5 hours